Dianthus Therapeutics targets severe autoimmune diseases with DNTH103. Read more on DNTH's promise amid competitive ...

Roivant Sciences secures $5.2B for advancing late-stage drugs like IMVT-1402 & brepocitinib. Click here to read an analysis ...

KORU Medical Systems, Inc.’s KRMD share price has surged by 5.80%, which has investors questioning if this is right time to ...

Immunovant stated that these changes are part of its parent entity, Roivant, increasing operational involvement and strategic ...

Roivant Sciences is making serious changes to subsidiary Immunovant, announcing Monday a series of C-suite changes and new disease targets.

That means the future of Roivant is tied to the success, or otherwise, of Immunovant’s attempts to break into the FcRn market ...

Ernesto Olvera, a Visalia resident, has been fighting a rare autoimmune disease known as chronic inflammatory demyelinating ...

The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and ...

In a multicenter randomized phase 3 trial, stapokibart, a humanized monoclonal antibody that targets IL-4R alpha, significantly improved daily nasal and ocular symptom scores during the pollen ...

chronic inflammatory demyelinating polyneuropathy, Alzheimer’s disease, Parkinson’s disease, age-related macular degeneration, and other neurological diseases. The neurology pipeline currently has ...

and chronic inflammatory demyelinating polyneuropathy (CIDP) with a favorable safety profile. ADAPT-NXT Part B data demonstrated clinically meaningful improvements as early as Week 1 with Vyvgart ...

and chronic inflammatory demyelinating polyneuropathy (CIDP) with a favorable safety profile. ADAPT-NXT Part B data demonstrated clinically meaningful improvements as early as Week 1 with Vyvgart’s bi ...